FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028512418> ?p ?o ?g. }

• W3028512418 endingPage "S91" @default.
• W3028512418 startingPage "S90" @default.
• W3028512418 abstract "Background & Aim Chronic graft-versus-host disease (cGVHD) is a long-term complication of allogeneic hematopoietic stem cell transplantation associated with poor quality of life and increased morbidity and mortality. Currently, there is no standardized treatment available for patients who do not respond to steroids. As an alternative to immunosuppressants, mesenchymal stem cells (MSCs) have been suggested to treat steroid-refractory GVHD. Methods, Results & Conclusion To evaluate the safety and efficacy of repeated infusions of MSCs, we treated ten severe steroid-refractory cGVHD patients intravenously with MSCs produced from third-party bone marrow donors biweekly for a total of four doses. Each dose contained 1 × 106 cells/kg body weight from the same donor and same passage. Ten patients with various organ involvement were enrolled. All ten patients received their planned four doses of MSCs, administering a total of 40 infusions during the study. MSCs were well tolerated with no immediate or delayed toxicities. After 8 weeks of the first MSC infusion, all ten patients showed partial response showing alleviation in clinical symptoms and increased quality of life. Two patients died due to relapse from primary disease. Immunological analyses revealed reduction in inflammatory markers including ST2, CXCL10, and osteopontin following MSC treatment. Repeated infusions of MSCs was feasible and safe and may be an effective salvage therapy in patients with steroid-refractory cGVHD. Further large-scale clinical studies with long-term follow up is needed in the future to determine the role of MSCs in cGVHD. Chronic graft-versus-host disease (cGVHD) is a long-term complication of allogeneic hematopoietic stem cell transplantation associated with poor quality of life and increased morbidity and mortality. Currently, there is no standardized treatment available for patients who do not respond to steroids. As an alternative to immunosuppressants, mesenchymal stem cells (MSCs) have been suggested to treat steroid-refractory GVHD. To evaluate the safety and efficacy of repeated infusions of MSCs, we treated ten severe steroid-refractory cGVHD patients intravenously with MSCs produced from third-party bone marrow donors biweekly for a total of four doses. Each dose contained 1 × 106 cells/kg body weight from the same donor and same passage." @default.
• W3028512418 created "2020-05-29" @default.
• W3028512418 creator A5021692797 @default.
• W3028512418 creator A5031769614 @default.
• W3028512418 creator A5032835145 @default.
• W3028512418 creator A5034475527 @default.
• W3028512418 creator A5054167960 @default.
• W3028512418 creator A5058670098 @default.
• W3028512418 creator A5066791469 @default.
• W3028512418 creator A5081811380 @default.
• W3028512418 date "2020-05-01" @default.
• W3028512418 modified "2023-10-16" @default.
• W3028512418 title "A Prospective Phase I/II Clinical Study Evaluating the Clinical and Immune Responses of Repeated MSCs Infusions in Steroid-Refractory Chronic GVHD Patients" @default.
• W3028512418 doi "https://doi.org/10.1016/j.jcyt.2020.03.154" @default.
• W3028512418 hasPublicationYear "2020" @default.
• W3028512418 type Work @default.
• W3028512418 sameAs 3028512418 @default.
• W3028512418 citedByCount "0" @default.
• W3028512418 crossrefType "journal-article" @default.
• W3028512418 hasAuthorship W3028512418A5021692797 @default.
• W3028512418 hasAuthorship W3028512418A5031769614 @default.
• W3028512418 hasAuthorship W3028512418A5032835145 @default.
• W3028512418 hasAuthorship W3028512418A5034475527 @default.
• W3028512418 hasAuthorship W3028512418A5054167960 @default.
• W3028512418 hasAuthorship W3028512418A5058670098 @default.
• W3028512418 hasAuthorship W3028512418A5066791469 @default.
• W3028512418 hasAuthorship W3028512418A5081811380 @default.
• W3028512418 hasConcept C121332964 @default.
• W3028512418 hasConcept C126322002 @default.
• W3028512418 hasConcept C141071460 @default.
• W3028512418 hasConcept C142424586 @default.
• W3028512418 hasConcept C142724271 @default.
• W3028512418 hasConcept C197934379 @default.
• W3028512418 hasConcept C198826908 @default.
• W3028512418 hasConcept C2777408962 @default.
• W3028512418 hasConcept C2779972918 @default.
• W3028512418 hasConcept C2911091166 @default.
• W3028512418 hasConcept C71924100 @default.
• W3028512418 hasConcept C87355193 @default.
• W3028512418 hasConcept C90924648 @default.
• W3028512418 hasConceptScore W3028512418C121332964 @default.
• W3028512418 hasConceptScore W3028512418C126322002 @default.
• W3028512418 hasConceptScore W3028512418C141071460 @default.
• W3028512418 hasConceptScore W3028512418C142424586 @default.
• W3028512418 hasConceptScore W3028512418C142724271 @default.
• W3028512418 hasConceptScore W3028512418C197934379 @default.
• W3028512418 hasConceptScore W3028512418C198826908 @default.
• W3028512418 hasConceptScore W3028512418C2777408962 @default.
• W3028512418 hasConceptScore W3028512418C2779972918 @default.
• W3028512418 hasConceptScore W3028512418C2911091166 @default.
• W3028512418 hasConceptScore W3028512418C71924100 @default.
• W3028512418 hasConceptScore W3028512418C87355193 @default.
• W3028512418 hasConceptScore W3028512418C90924648 @default.
• W3028512418 hasIssue "5" @default.
• W3028512418 hasLocation W30285124181 @default.
• W3028512418 hasOpenAccess W3028512418 @default.
• W3028512418 hasPrimaryLocation W30285124181 @default.
• W3028512418 hasRelatedWork W1931457273 @default.
• W3028512418 hasRelatedWork W1994968709 @default.
• W3028512418 hasRelatedWork W2052860239 @default.
• W3028512418 hasRelatedWork W2139350974 @default.
• W3028512418 hasRelatedWork W2141777411 @default.
• W3028512418 hasRelatedWork W2559999242 @default.
• W3028512418 hasRelatedWork W2989865626 @default.
• W3028512418 hasRelatedWork W3030698977 @default.
• W3028512418 hasRelatedWork W3032005908 @default.
• W3028512418 hasRelatedWork W4237424193 @default.
• W3028512418 hasVolume "22" @default.
• W3028512418 isParatext "false" @default.
• W3028512418 isRetracted "false" @default.
• W3028512418 magId "3028512418" @default.
• W3028512418 workType "article" @default.